Attached files
| file | filename |
|---|---|
| 10-Q - Lineage Cell Therapeutics, Inc. | form10-q.htm |
| EX-31 - Lineage Cell Therapeutics, Inc. | ex-31.htm |
| EX-3.1 - Lineage Cell Therapeutics, Inc. | ex3-1.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of BioTime, Inc. (the “Company”) for the quarter ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Michael D. West, Co-Chief Executive Officer, Aditya Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and | |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 10, 2018
| /s/ Michael D. West | |
| Michael D. West, Ph.D. | |
| Co-Chief Executive Officer | |
| /s/ Aditya Mohanty | |
| Aditya Mohanty | |
| Co-Chief Executive Officer | |
| /s/ Russell L. Skibsted | |
| Russell L. Skibsted | |
| Chief Financial Officer |